Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453172 | 1.00 | CYP11B1 (0.36) | CYP11B1CYP11B2MAPTP2RX7SUCNR1 | |
| SCHEMBL4457484 | 1.00 | CYP11B1 (0.36) | CYP11B1CYP11B2MAPTP2RX7SUCNR1 | |
| SCHEMBL4185981 | 0.91 | SUCNR1 (0.38) | CYP11B1CYP11B2MAPTP2RX7SUCNR1 | |
| SCHEMBL4190731 | 0.91 | SUCNR1 (0.38) | CYP11B1CYP11B2MAPTP2RX7SUCNR1 | |
| SCHEMBL4194972 | 0.91 | SUCNR1 (0.38) | CYP11B1CYP11B2MAPTP2RX7SUCNR1 | |
| SCHEMBL4184766 | 0.88 | MAPT (0.45) | CYP11B1CYP11B2MAPTSUCNR1CHRNA7 | |
| SCHEMBL4453542 | 0.88 | MAPT (0.45) | CYP11B1CYP11B2MAPTSUCNR1CHRNA7 | |
| SCHEMBL4185760 | 0.88 | MAPT (0.45) | CYP11B1CYP11B2MAPTSUCNR1CHRNA7 | |
| SCHEMBL4189782 | 0.87 | RORC (0.40) | CYP11B1CYP11B2SUCNR1CCR2KCNH2 | |
| SCHEMBL4188271 | 0.87 | RORC (0.40) | CYP11B1CYP11B2SUCNR1CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | SHBG, AR, FSHR | CYP11B1 94/4885CYP11B2 51/4885MAPT 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.